+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Vectura Group Plc - Strategic SWOT Analysis Review

Vectura Group Plc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - The summarization of the company’s business strategy.
  • SWOT analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.

Highlights

Vectura Group Plc (Vectura) is a formulation, device design and development company. It focuses on the development of inhaled airways products through an integrated inhaled drug delivery platform. Its major products include dry powder inhalers (DPI) and metered dose inhalers (MDI) for patients suffering from airways diseases such as asthma, chronic obstructive pulmonary disease (COPD) and other ailments. It offers formulation development, pharmaceutical analysis, device platforms, process development & technical transfer, product manufacturing and regulatory services. Th company has partnership and license agreements with global biotechnology and pharmaceutical companies to develop a portfolio of drugs, including inhaled in-market products and inhaled generics. Vectura is headquartered in Chippenham, Wiltshire, the UK.

Vectura Group Plc Key Recent Developments

Sep 27,2022: Vectura secures planning approval to build £58m for Inhalation Centre of Excellence
Sep 27,2022: £58m Inhalation Centre of Excellence granted planning permission

Reasons to Buy

  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with a detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.

Table of Contents

Section 1 - About the Company
  • Vectura Group Plc - Key Facts
  • Vectura Group Plc - Key Employees
  • Vectura Group Plc - Key Employee Biographies
  • Vectura Group Plc - Major Products and Services
  • Vectura Group Plc - History
  • Vectura Group Plc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Vectura Group Plc - Business Description
  • Vectura Group Plc - SWOT Analysis
  • SWOT Analysis - Overview
  • Vectura Group Plc - Strengths
  • Vectura Group Plc - Weaknesses
  • Vectura Group Plc - Opportunities
  • Vectura Group Plc - Threats
  • Vectura Group Plc - Key Competitors
Section 3 - Company’s Lifesciences Financial Deals and Alliances
  • Vectura Group Plc, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Vectura Group Plc, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • Vectura Group Plc, Recent Deals Summary
Section 4 - Company’s Recent Developments
  • Sep 27, 2022: Vectura secures planning approval to build £58m for Inhalation Centre of Excellence
  • Sep 27, 2022: £58m Inhalation Centre of Excellence granted planning permission
Section 5 - Appendix
  • Methodology
  • About the Publisher
  • Contact Us
  • Disclaimer
List of Tables
  • Vectura Group Plc, Key Facts
  • Vectura Group Plc, Key Employees
  • Vectura Group Plc, Key Employee Biographies
  • Vectura Group Plc, Major Products and Services
  • Vectura Group Plc, History
  • Vectura Group Plc, Other Locations
  • Vectura Group Plc, Subsidiaries
  • Vectura Group Plc, Key Competitors
  • Vectura Group Plc, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Vectura Group Plc, Medical Equipment, Deals By Type, 2017 to YTD 2023
  • Vectura Group Plc, Recent Deals Summary
List of Figures
  • Vectura Group Plc, Medical Equipment, Deals By Year, 2017 to YTD 2023
  • Vectura Group Plc, Medical Equipment, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Inspiration Healthcare Group plc
  • Aerogen Ltd
  • Consort Medical Ltd
  • AstraZeneca Plc
  • Theravance Biopharma UK Ltd